Headquartered in Foster City, California, Gilead Sciences, Inc. (GILD) is a global biopharmaceutical leader committed to ...

Several of the events took place at ‘upscale restaurants’ in San Francisco, at costs of up to $163 per person, according to ...

Gilead Sciences (GILD) closed at $110.17 in the latest trading session, marking a +1.75% move from the prior day. This change outpaced the S&P 500's 0.06% gain on the day. On the other hand, the Dow ...

Attorney General Dave Sunday announced that Pennsylvania will receive over $1 million as part of a $202 million multistate ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

"Government health care dollars are precious and must be used without favor in order to achieve the highest possible health ...

Gilead Sciences (NasdaqGS:GILD) recently announced a partnership with the Global Fund to supply lenacapavir for HIV ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

Pharma giant Gilead Sciences agreed to pay hundreds of millions of dollars to state health insurance programs after admitting ...

The World Health Organization on Monday recommended Gilead's lenacapavir, a twice-yearly injection, as a tool to prevent HIV ...

The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences lenacapavir, a twice-yearly injection, for preventing HIV infection in adults and adolescents.

Gilead, Global Fund Finalize Plan to Supply HIV Prevention Drug to Poor Countries By Deena Beasley and Jennifer Rigby (Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and ...